Now, a new evidence review has identified the most effective treatments for people who suffer from chronic hives.

Patients with moderate to severe atopic dermatitis experienced a 71% decrease in Eczema Area and Severity Index scores from ...

With few real-life studies that have specifically focused on how atopic dermatitis (AD) affects patients living with the ...

Dupilumab in patients with diffuse type 2 CRSwNP had beneficial changes in nasal passage microbiota but did not alter gastrointestinal microbiota.

Treatment with dupilumab is associated with weight gain in about two thirds of adults with atopic dermatitis over 3-6 months, ...

A new international study led by researchers at McMaster University has identified the most effective and safest treatments ...

Patients with asthma and allergic bronchopulmonary aspergillosis experienced improvements with dupilumab, according to data ...

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Introducing lebrikizumab for severe atopic dermatitis in Italy may result in cost savings for the national health system, a ...

Dupixent ® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase 3 trial Data ...

Since its release in 2017, dupilumab (a fully humanized monoclonal antibody that blocks IL-4 and IL-13) has transformed the therapeutic landscape for managing atopic dermatitis (AD) and other ...

PARIS and TARRYTOWN, N.Y., Oct. 16, 2018 /PRNewswire/ -- Two pivotal Phase 3 placebo-controlled trials evaluating Dupixent ® (dupilumab) in adults with inadequately-controlled chronic ...